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Themicrobiome dysbiosis caused by antibiotic treatment has been associated with both susceptibility to and relapse of Clostrid-
ium difficile infection (CDI). Bacteriophage (phage) therapy offers target specificity and dose amplification in situ, but few stud-
ies have focused on its use in CDI treatment. This mainly reflects the lack of strictly virulent phages that target this pathogen.
While it is widely accepted that temperate phages are unsuitable for therapeutic purposes due to their transduction potential,
analysis of seven C. difficile phages confirmed that this impact could be curtailed by the application of multiple phage types.
Here, host range analysis of six myoviruses and one siphovirus was conducted on 80 strains representing 21 major epidemic and
clinically severe ribotypes. The phages had complementary coverage, lysing 18 and 62 of the ribotypes and strains tested, respec-
tively. Single-phage treatments of ribotype 076, 014/020, and 027 strains showed an initial reduction in the bacterial load fol-
lowed by the emergence of phage-resistant colonies. However, these colonies remained susceptible to infection with an unrelated
phage. In contrast, specific phage combinations caused the complete lysis of C. difficile in vitro and prevented the appearance of
resistant/lysogenic clones. Using a hamster model, the oral delivery of optimized phage combinations resulted in reduced C. dif-
ficile colonization at 36 h postinfection. Interestingly, free phages were recovered from the bowel at this time. In a challenge
model of the disease, phage treatment delayed the onset of symptoms by 33 h compared to the time of onset of symptoms in un-
treated animals. These data demonstrate the therapeutic potential of phage combinations to treat CDI.
Clostridium difficile (Peptoclostridium difficile) is responsible forapproximately 39% of the cases of antibiotic-associated diar-
rhea in the Western world, causing death in 10% of patients (1).
Two of the main problems associated with disease prevention in-
clude the diverse virulent ribotypes (strains) that cause infections
that are resistant to and respond differently to antibiotic treatment
and the production of spores that are impervious to chemical
decontamination (2–4). The prevalence of C. difficile, the cost of
infection control, and the challenge of finding alternative treat-
ments all contribute to the fact that infection with this organism
remains a significant clinical and financial burden to the health
care system (5, 6).
Acute C. difficile infection (CDI) is treated using antibiotics,
with three options currently being available: metronidazole, van-
comycin, and fidaxomicin (7–9). Metronidazole and vancomycin
are the most commonly prescribed and are given either individu-
ally or in combination. This strategy has been implemented de-
spite the fact that metronidazole is not effective against all ri-
botypes and that vancomycin is the antibiotic of last resort against
many other multidrug-resistant pathogens and, thus, its pro-
longed use is discouraged (8, 9). Fidaxomicin has an effect similar
to that of vancomycin, but the high cost associated with this anti-
biotic also limits its clinical use (10, 11). Importantly, a major
disadvantage associated with antibiotic use for the treatment of
CDI is the risk of exacerbating further the dysbiosis (imbalance) of
the microbiota. This results in normal gut commensals being re-
duced or removed, thus allowing C. difficile to effectively colonize
this niche (12). Furthermore, antibiotic therapy of this infection is
often associated with high recurrence rates and provides an op-
portunity for antibiotic resistance to emerge (13). This negative
association with antibiotic use further highlights the need to iden-
tify alternative, more effective strategies to treat CDIs.
Phage therapy offers several advantages over therapy with con-
ventional antibiotics (12, 14, 15). Phages are viruses which specif-
ically infect bacteria, and phage therapy exploits the specific na-
ture of these phage-bacterium interactions (16). The potential use
of phages for the treatment of infectious diseases has been exten-
sively discussed, and phages have been shown to effectively reduce
or remove specific bacteria responsible for a wide range of infec-
tions in both animals and humans (14, 17–19). Pertinent to CDI is
the minimal deleterious effect that they have on the gut microbi-
ota; consequently, their use prevents further dysbiosis. Further-
more, phages replicate in a self-limiting manner at a localized site
of infection; thus, their effective dosage is amplified (20). A third
useful attribute is their ability to penetrate the complex biofilm
environments found inC. difficile-associated pseudomembranous
plaques (19, 21, 22).
Phage therapy is used widely in Russia and Georgia, where
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phage cocktails targeting many bacterial species, including Staph-
ylococcus, Streptococcus, Pseudomonas, Proteus, and Escherichia
coli, are available as over-the-counter pharmaceutical products
(16, 23). In Poland, phage therapy has been successfully used to
treat chronic and antibiotic-resistant suppurative infections (24).
Furthermore, there is an increasing interest in their potential use
in many Western countries, and several clinical trials are in prep-
aration (23, 25, 26). Interestingly, phages have been approved for
use in food products, demonstrating their increasing acceptability
as a safe and useful antimicrobial agent (27, 28).
To date, treatments based on phage therapy have not been
developed to treat CDIs. This is the case despite recent recommen-
dations that this type of therapy be offered as an alternative to
conventional antibiotic treatment for CDI (12, 14, 15). The reason
for this lack of development is largely because C. difficile has not
been a target pathogen in the countries where phage therapy is
used. Advances in this area have also been limited by the lack of
strictly virulent phages that infect this pathogen and by the fact
that the isolation of phages for this organism can be challenging,
so in some studies, only 1 or 2 C. difficile phages have been isolated
and tested (29–31). In species where no lytic phages have been
identified, the only pragmatic option for the development of
phage therapeutics is to test the efficacy of multiple wild-type
phages to determine their efficacy per se and, potentially, to de-
velop the lysogenic phages further using engineering approaches.
C. difficile phages that can access the lytic life cycle have been
isolated both in our laboratory and elsewhere (32–37), but to date,
no studies have described the use of phage cocktails/combinations
against C. difficile (14). Here, we determined the activity of seven
phages individually and in combination against clinically relevant
ribotypes of C. difficile. Using individual phages and phage com-
binations, we demonstrate the synergy of phage combinations for
the effective clearance of C. difficile. Optimized phage combina-
tions were also shown to reduce colonization and disease symp-
toms and extend longevity in a hamster model of CDI. Our results
support the potential application of phage combinations for the
targeted eradication of CDI.
MATERIALS AND METHODS
Bacterial strains and culture conditions. The C. difficile isolates used in
this study include those from our laboratory collection and those kindly
provided by Richard Stabler (London School of Hygiene and Tropical
Medicine, London, United Kingdom), Trevor Lawley (Wellcome Trust
Sanger Institute, Cambridge, United Kingdom), and Mark Wilcox (Uni-
versity of Leeds, Leeds, United Kingdom), who also donated the U.S.
strains. The Australian strains were a kind gift from Dena Lyras (Monash
University, Australia) and Tom Borody (Center for Digestive Diseases,
Australia). C. difficile strains were subcultured on brain heart infusion
(BHI) agar (Oxoid, Ltd., United Kingdom) supplemented with 7% defi-
brinated horse blood (TCS Biosciences, Ltd., United Kingdom). The
strains were preserved in Protect bacterial preservers (Abtek Biologicals
Ltd., Liverpool, United Kingdom) and stored at 80°C. Strains were
characterized using the primers 5=-TTGAGCGATTTACTTCGGTAAAG
A-3= and 5=-CCATCCTGTACTGGCTCACCT-3= targeting the C. difficile
16S rRNA gene (38) and capillary gel electrophoresis-based PCR ribotyp-
ing with primers 5=-GTGCGGCTGGATCACCTCCT-3= and 5=-CCCTG
CACCCTTAATAACTTGACC-3= to amplify the 16S-23S rRNA genes
(39). Data analysis was performed using Peak Scanner software (Applied
Biosystems, United Kingdom) and the Multivariate statistical package
(version 3.1).
Phage isolation and propagation and host range analysis. Phages
were isolated from the enrichment of estuarine samples and the induction
of estuarine isolates (40, 41). The phages were initially screened for activ-
ity, performed by the observation of lysis on a lawn of bacteria (42).
Briefly, 3 ml of a 0.5% BHI agar overlay containing 0.01 M CaCl2, 0.4 M
MgCl2, and 250 l of an overnight culture of indicator bacteria grown in
fastidious anaerobic broth (FAB; BioConnections, Leeds, United King-
dom) was prepared. Aliquots of 10 l of the phage samples were applied
on the agar overlay and allowed to dry for2 min at room temperature
before incubation at 37°C anaerobically overnight. Phages were made
clonal through subjection to five rounds of purification using a plaque
assay as previously described (34, 41). The morphology of the phages was
identified using transmission electron microcopy (TEM) analysis (43).
The presence of temperate phages within the manufacturing hosts was
ascertained by subjecting the cultures to 3 g/ml norfloxacin (Sigma-
Aldrich, Dorset, United Kingdom) or mitomycin C (Fisher Scientific,
Loughborough, United Kingdom) and monitoring for spontaneous re-
lease using TEM. The host range of the seven phages was tested as de-
scribed above using 108 PFU/ml of lysates (42).
Phage DNA extraction, sequencing, and phylogenetic analysis.
Genomic DNA was extracted from the crude lysates using a modified
phenol-chloroform-isoamyl alcohol method. Briefly, the 1-ml lysates
with 109 PFU/ml of phages were treated with 12.5 mM MgCl2 (Acros
Organics, NJ, USA), 0.8 U/ml of DNase (Sigma, USA), and 0.1 mg/ml of
RNase (Sigma, USA) (final concentrations) and incubated at room tem-
perature for 1 h to eliminate bacterial DNA. Afterwards, EDTA (Sigma,
USA), proteinase K (Fisher Scientific, Germany), and sodium dodecyl
sulfate (Fisher Scientific, United Kingdom) were added to final concen-
trations of 20 mM, 0.5 mg/ml, and 0.5%, respectively, before incubation at
55°C for an additional hour to digest the phage capsid. DNA material was
extracted with an equal volume of phenol-chloroform-isoamyl alcohol
(25:24:1, vol/vol/vol) and centrifuged at 15,000 g for 5 min. The aque-
ous layer obtained was treated with 0.3 M sodium acetate (Fisher Scien-
tific, United Kingdom) and 2 volumes of ice-cold ethanol to precipitate
the DNA. After incubation for 10 min on ice, the DNA was eluted by
centrifugation at 21,000  g for 20 min, and the resultant pellet was
washed once with 0.5 ml of 70% ethanol before it was dissolved in 5 mM
Tris HCl. The DNA quality and quantity were analyzed using a NanoDrop
2000 spectrophotometer and a Qubit double-stranded HS assay kit on a
Qubit fluorometer (Thermo Scientific, United Kingdom), respectively,
before the DNA was sequenced using Illumina HiSeq sequencing. Gene
prediction was conducted using the Rapid Annotation Using Subsystem
Technology (RAST) server (44) and visualized with Geneious R8 software
(45). Minor capsid genes from all the sequenced genomes and C. difficile
phage sequences were extracted from the National Center for Biotechnol-
ogy Information (NCBI) database. The evolutionary history of the mi-
nor capsid genes was inferred using the maximum likelihood method in
MEGA (version 6.06) software, and the tree was visualized with the Fig-
Tree (version 1.4.2) program.
Phage-bacterium coinfection assay. High plaquing efficiencies by
five of the seven phages (phiCDHM1 to phiCDHM3, phiCDHM5, and
phiCDHM6) were observed on strains CD105HE1 and CD105LC2. Sim-
ilarly, phiCDHS1 propagated efficiently on strain R20291. These phages
and C. difficile strains were selected for further in vitro analysis. To prepare
liquid cultures, a single colony from BHI agar-supplemented medium was
inoculated into FAB and incubated overnight. Fresh cultures were pre-
pared by subculturing 1% of the overnight culture into prereduced BHI
broth; growth was monitored by measuring the optical density (OD) at
550 nm (OD550). Once the cultures reached an OD of 0.2  0.01 (10
7
CFU/ml cells), phage lysates were added at a multiplicity of infection
(MOI) of 10. The MOI remained constant even when combinations of
phages were prepared by combining equal amounts of phages. Cultures
were monitored over 24 h, and viability counts were recorded hourly until
5 h and then again at 24 h.
Analysis of phage-resistant and lysogenic bacteria. To isolate phage-
resistant and lysogenic bacterial colonies, a 10-fold dilution of the bacte-
rial culture at an OD550 of 0.2 0.01 was prepared in BHI broth. Approx-
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imately 10 l of the diluted bacterial culture was applied on 3-ml BHI
semisolid agar overlays on brucella agar (Oxoid, United Kingdom) sup-
plemented with 5% blood, 5 mg/liter hemin, and 1 mg/liter vitamin K
(46). Similarly, the diluted cultures were also applied to semisolid agar
overlays containing 250 l of 109 PFU/ml of the most active phages
(phiCDHM1, phiCDHM2, or phiCDHM3). Colonies recovered from the
phage-treated media were subsequently purified from phage contamina-
tion by serial passage on BHI agar plates supplemented with 7% defi-
brinated horse blood on at least three occasions. All resistant colonies
from the phage treatments were identified to beC. difficileusing 16S rRNA
analysis (38). The bacteria were further characterized for the presence or
absence of the phages using primers specific for the NACHT gene of
phages phiCDHM1 and phiCDHM3 (5=-GAAGCACTTGGAAAACAAA
GG-3= and 5=-CGCAAGAAGCATCAAAAACA-3=) (14) and the tail pro-
tein gene of phage phiCDHM2 (5=-GAGGGCAGGAATAAGAAAAGC-3=
and 5=-GATTCCCTATCCTCAACTACGC-3=). The sensitivity of resis-
tant, lysogenic, and wild-type bacteria to phages phiCDHM1 to
phiCDHM3, phiCDHM5, and phiCDHM6 was determined using a spot
test with serially diluted phage lysates.
Efficacy of phage treatment on colonization in vivo. The efficacy of
phage treatment was assessed in vivo using the Syrian Golden hamster
model of acute C. difficile infection. This model reflects many of the clin-
ical features of the disease, including toxin-mediated diarrhea and tissue
pathology (29, 30, 47). All procedures were conducted in strict accordance
with the Animals Act (Scientific Procedures, 1986) and were approved by
the Home Office, United Kingdom (project license number PPL60/4218).
Female Syrian Golden hamsters that weighed approximately 100 g (bred
in-house) were housed individually in sterilized cages and given irradiated
water and pelleted standard B&K rat and mouse food (DBM, Scotland) ad
libitum. Each animal received 30 mg of clindamycin phosphate per kg of
body weight orogastrically in a single dose administered 5 days before
challenge. At approximately 10 min prior to challenge or subsequent
phage treatment, the animals were treated with 400 l 1 M sodium bicar-
bonate (Sigma, United Kingdom) to reduce stomach acid. Animals were
infected with 0.2 ml of 104 CFU/ml spores of the C. difficile CD105HE1
strain (Fig. 1A and B) and subsequently treated with 0.8 ml of 1  108
PFU/ml as either a single phage or a combination of phages. The first dose
was given at the time of challenge, with subsequent doses being given
every 8 h until the scheduled endpoint of 36 h (Fig. 1A). At this point the
animals were culled and the impact of phage treatment was quantified by
enumeration of the total bacterial load (spores and vegetative cells) in the
cecum and colon. This was achieved by removing and opening each sec-
tion longitudinally. The contents were removed by gentle washing in 10
ml phosphate-buffered saline (PBS) (lumen-associated [LA] bacteria),
and the viable counts of the recovered bacteria were determined by plating
serial 10-fold dilutions on selective cefoxitin-cycloserine-egg yolk (CCEY)
agar (BioConnections, Leeds, United Kingdom) plates. To evaluate the
level of more intimately associated organisms, the tissue was further
washed in 10 ml PBS and homogenized in 5 ml of PBS for 1 min using a
Lablender 80 stomacher (Seward Medical, United Kingdom) (tissue-as-
sociated [TA] bacteria), and the homogenates were again diluted and
plated as described above. To determine the numbers of spores present,
the same samples were heated for 15 min at 65°C, and the numbers of
spores present were determined by serial dilution and plating of these
samples. Results are shown as the mean number of bacteria recovered
from six to eight animals.
For analysis of disease onset, two groups of six animals each were
treated and infected as described above, except that treatment with phages
continued every 8 h until the experimental endpoint (Fig. 1B). Animals
were monitored throughout using a combination of observation and te-
lemetry to measure the core body temperature. Previous experience has
shown that animals are unable to recover from disease when the core body
temperature drops by 2°C to 35°C, and this decrease provides the exper-
imental endpoint.
Statistical analyses were performed using GraphPad Prism (version 6)
software, and a Mantel-Cox log-rank statistical test was used to determine
significant differences in survival times between hamsters infected with
the different C. difficile strains. P values of0.05 were considered signif-
icant.
RESULTS
Phage classification and relationships. Seven phages (phiCDHM1
to phiCDHM6, and phiCDHS1) were isolated and examined in
this study (Table 1). The phages were characterized according to
their morphology, host range, and molecular diversity. Six
(phiCDHM1 to phiCDHM6) are myoviruses, and one
(phiCDHS1) is a siphovirus (Table 1). Phylogenetic analysis of the
putative minor capsid gene revealed that the phages are diverse
but form discrete groups consistent with their morphology (Fig. 2;
FIG 1 Schematic representation of timing of infection and phage dosing in vivo. (A) To determine the impact of the phages on colonization, animals were
infected and dosed with a single phage or a combination of phages every 8 h for 36 h. Animals culled at this point showed no symptoms, even though they
subsequently showing high levels of bacterial colonization. No toxin was detected in any animal at this time point. (B) To determine the protective efficacy of the
phages, animals were infected and treated with the phages as described in the legend to panel A. Treatment was continued until the body temperature of the
animal reached 35°C, at which point the animal was culled and the level of colonization of tissue was determined. All animals were made sensitive to C. difficile
by oral treatment with clindamycin 5 days prior to challenge with bacterial spores.
Nale et al.
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see also Table S1 in the supplemental material). The terminal
groups to which the phages belong are supported by high boot-
strap values (75%), but the relatedness of the groups varies.
Further genomic analysis has shown that, consistent with all other
known C. difficile phages, the genomes of these phages encode
integrase genes, and thus, the phages can potentially access the
lysogenic life cycle. However, all seven phages clearly access the
lytic cycle following initial infection of clinically relevant isolates.
Phage propagation. To produce an optimized product for
therapeutic development, phages were propagated on specific
bacterial strains that generate high titers. These bacterial strains
are referred to as the manufacturing hosts. Three C. difficile iso-
lates, CD105HE1 (ribotype 076, equine isolate) (48), CD105HS1
(ribotype 012, environmental isolate) (40), and CD105LC1 (ri-
botype 027, human isolate) (49), were required to propagate the
seven phages (Table 1). Five of the phages (phiCDHM1 to
phiCDHM3, phiCDHM5, and phiCDHM6) were propagated on
CD105HE1 and, when optimized procedures were followed,
produced phages at titers of 1010 PFU/ml. phiCDHM4 was prop-
agated on CD105HS1, and phiCDHS1 was propagated on
CD105LC1. Both produced phages at titers of 109 PFU/ml.
The manufacturing hosts were characterized according to the
content and activity of their prophages, to determine if any such
prophages contributed to the activity of the final product. Previ-
ously, genome sequencing has shown that the genomes of
CD105HS1, CD105HE1, and CD105LC1 encode one prophage
each (40, 48, 49). However, no prophages were spontaneously
released under the optimized conditions used during the propa-
gation of any of the seven phages. In contrast, the prophages could
be induced using 3 g/ml of mitomycin C or norfloxacin (see
Table S2 in the supplemental material). Fortunately, none of the
prophages from the manufacturing hosts could infect their host
strain or any of the clinically relevant bacterial isolates tested.
Phage host ranges. For a phage-based product to be effective,
TABLE 1 Characteristics of the seven phages examined in this studya
Phage Family
Tail length/tail
diam (nm)
Capsid diam
(nm) Source
Manufacturing
host TEM image
phiCDHM1 Myoviridae 110/20 60 Induction CD105HE1
phiCDHM2 Myoviridae 220/20 50 Enrichment CD105HE1
phiCDHM3 Myoviridae 120/20 60 Induction CD105HE1
phiCDHM4 Myoviridae 220/20 50 Induction CD105HS1
phiCDHM5 Myoviridae 230/20 50 Enrichment CD105HE1
phiCDHM6 Myoviridae 230/20 50 Enrichment CD105HE1
phiCDHS1 Siphoviridae 270/20 70 Enrichment CD105LC1
a The phages were isolated from enrichment of estuarine samples or induction of C. difficile isolates from the same environment, as indicated. Six of the phages (phiCDHM1 to
phiCDHM6) are myoviruses, while phiCDHS1 is a siphovirus. Three phages (phiCDHM1, phiCDHM3, and phiCDHM4) were induced from environmental C. difficile isolates,
while phiCDHM2, phiCDHM5, phiCDHM6, and phiCDHS1 were isolated from enrichment of the samples. Bars, 60 nm.
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it must target the most clinically relevant strains of C. difficile. To
determine the host range of the phages, the most prevalent dis-
ease-causing ribotypes from the United Kingdom, the United
States, and Australia (see Fig. S1 and Table S3 in the supplemental
material) were identified through an extensive literature search,
with 21 clinically relevant ribotypes being identified on the basis of
prevalence and severity in these three countries. They were ri-
botypes 001, 002, 003, 005, 012, 013, 014/020, 015, 017, 018, 023,
FIG 2 Phylogenetic analysis of the minor capsid gene of C. difficile phages. The evolutionary history of C. difficile phages based on the capsid gene was inferred
using the maximum likelihood method based on the Whelan and Goldman frequency model (74). An initial tree(s) for the heuristic search was obtained by
applying the neighbor-joining method to a matrix of pairwise distances estimated using a JTT model. The percentage of trees in which the associated taxa
clustered together is shown next to the branches. The tree is drawn to scale, with branch lengths being measured as the number of substitutions per site. The
analysis involved 22 C. difficile phage minor capsid sequences, including those of the 7 phages examined in this study (*) and one C. perfringens phage, phiCP39_0,
as an outgroup. The clades are consistent with the phage morphologies represented by blue (long-tailed myoviruses), green (siphoviruses), gray (small myovi-
ruses), and red (medium myoviruses) (75). The accession numbers of all the sequences used are found in Table S1 in the supplemental material. Evolutionary
analyses were conducted in the MEGA (version 6) program (76) and visualized with the FigTree (version 1.4.2) program.
Nale et al.
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026, 027, 078, 081, 087, 106, 107, 126, 127, and 262 (3, 6, 50–55).
In order to assess the host range on a wide range of C. difficile
strains, 80 isolates representing the 21 ribotypes were obtained
and used as targets in host range assays (see Fig. S1 and Table S3 in
the supplemental material).
The ability of the phages to lyse the 80 isolates of C. difficile was
tested using 10-l stocks of 108 PFU/ml inoculated on lawns of
bacteria. While the killing spectrum of individual phages varied
between ribotypes, the phages successfully lysed 18 (86%) of the
ribotypes and 62 (78%) of the C. difficile isolates tested. C. difficile
isolates from three ribotypes, 017, 126, and 262, were not sensitive
to any of the phages (see Table S3 in the supplemental material).
However, these ribotypes currently contribute to less than 6% of
cases of clinical disease in the United Kingdom (55) and to even
fewer cases in the United States and Australia. Work is ongoing to
increase the coverage through the isolation of phages for these
ribotypes.
The efficacy of phage lysis varied considerably. Three phages,
phiCDHM3, phiCDHS1, and phiCDHM5, were able to lyse the
most C. difficile isolates and ribotypes: 31 isolates of 12 ribotypes,
30 isolates of 11 ribotypes, and 20 isolates of 10 ribotypes, respec-
tively. Similarly, phiCDHM2, phiCDHM6, and phiCDHM1 had
relatively wide host ranges, lysing 22 C. difficile isolates of 9 ri-
botypes, 23 isolates of 9 ribotypes, and 16 isolates of 7 ribotypes,
respectively. Phage phiCDHM4 had the narrowest host range and
could lyse just 4 ribotypes, although interestingly, it was the only
phage to lyse ribotype 012 and thus provides coverage for this
important strain (Fig. 3A and B; see also Table S3 in the supple-
mental material).
Effect of phage treatments on C. difficile. In order for phages
to be effective therapeutics, they must significantly reduce the bac-
terial load in vivo by either eliminating all bacteria or reducing
them to a level whereby the immune system can subsequently
clear the organism. To determine the lytic capacity of individual
phages and combinations of phages, we compared the abilities of
five phages to lyse bacterial cultures in vitro over a 24-h time pe-
riod. The phages studied were phiCDHM1 to phiCDHM3,
phiCDHM5, and phiCDHM6, all of which can be propagated on
the same host, CD105HE1. Having a common manufacturing
host ensured that any lytic activity could be attributed to the spe-
cific phage and not to possible differences conferred by the host
bacterial strain. The activities of five of the phages were also deter-
mined using the clinical C. difficile isolate CD105LC2 (ribotype
014/020). This strain was selected for analysis as it is highly prev-
alent in the clinical setting and the strain was shown to be suscep-
tible to infection by the same five phages that infect CD105HE1.
Effects of single-phage treatments. Initially, phages were
tested in liquid culture, using an MOI of 10, and the efficacy of
killing was determined by testing the viable bacterial counts
(numbers of CFU per milliliter) in the culture. Most phages ini-
tially cleared the bacterial culture, but after 24 h bacterial regrowth
occurred (Fig. 4A). phiCDHM1 and phiCDHM2 were more effi-
cient than phiCDHM3, but phiCDHM5 and phiCDHM6 were
less efficient than the other three phages at clearing the cultures,
with no differences between the treated and control cultures being
observed by 24 h.
Replication and lysis by the phages took longer in clinical iso-
late CD105LC2 (ribotype 014/020) than in the manufacturing
host (CD105HE1), with culture clearance not being observed un-
til 5 h postinfection. phiCDHM2 was the most effective phage,
reducing bacterial counts to below the limit of detection by 5 h,
although regrowth was observed by 24 h (Fig. 4B). Treatment with
phiCDHM1 and phiCDHM3 also proved effective, with the
viability of the culture being reduced by 6 and 4 log units,
respectively, at 5 h. As observed previously, phiCDHM5 and
phiCDHM6 proved to be the least effective phages, facilitating
only a 2-log-unit reduction in bacterial numbers at 5 h.
Optimization of two-phage combinations. To determine the
optimal phage combinations, three of the most effective phages
and two less effective phages were systematically paired to-
gether as follows: phiCDHM1-phiCDHM2, phiCDHM1-
phiCDHM3, phiCDHM2-phiCDHM3, and phiCDHM4-
phiCDHM5 (Fig. 4C and D).
The most effective lysis was observed using a combination of
phages phiCDHM1 and phiCDHM2, which completely lysed
CD105HE1 at 2 h postinfection with no regrowth after 24 h.
Although bacteria could not be detected at 3 h postinfection
with phiCDHM2-phiCDHM3, the organisms were detected 2 h
later. In contrast phiCDHM1-phiCDHM3 and phiCDHM5-
phiCDHM6 were not as effective (Fig. 4C).
Interestingly, the same pattern of activity was also observed on
strain CD105LC2, with phiCDHM1-phiCDHM2 and phiCDHM2-
phiCDHM3 causing complete lysis of the bacteria with no subse-
quent bacterial regrowth (Fig. 4D). In contrast phiCDHM1-
phiCDHM3 and phiCDHM5-phiCDHM6 were less efficient and
caused 4- and 2-log-unit reductions, respectively.
Optimization of three- and four-phage combinations. The
results of these paired phage assays informed the in vitro testing
choice for three three-phage combinations and one four-phage
combination. For the three-phage combinations, the most effec-
tive phages were combined with one of either of the two less effec-
tive phages (Fig. 4E and F).
The best combination of phages for the lysis of CD105HE1
was phiCDHM1-phiCDHM2-phiCDHM3, which eliminated
all viable bacteria by 2 h postinfection. Both the phiCDHM1-
phiCDHM5-phiCDHM6 and phiCDHM2-phiCDHM5-phiCDHM6
combinations produced an approximately 4-log-unit reduction
by 24 h (Fig. 4E). Of note, the four-phage combination,
phiCDHM1-phiCDHM2-phiCDHM5-phiCDHM 6, resulted in a
6-log-unit reduction in bacterial recovery, but this was not as ef-
ficient as the best three-phage combination.
The best three-phage combination for CD105LC2 was also
phiCDHM1-phiCDHM2-phiCDHM3, which completely cleared
the cultures in 5 h, whereas phiCDHM1-phiCDHM5-phiCDHM6
completely cleared the cultures in 24 h. phiCDHM2-phiCDHM5-
phiCDHM6 was less effective and reduced the counts of the
CD105LC2 cultures to approximately 102 CFU/ml after 5 h, after
which growth appeared to be stationary (Fig. 4F). However, the
most effective combination for this strain was the four-phage
combination, phiCDHM1-phiCDHM2-phiCDHM4-phiCDHM6,
which cleared the bacterial culture after 3 h with no further regrowth.
Sensitivity of phage-resistant and lysogenic CD105LC2. To
determine why some phage combinations were more effective
than the individual phage treatments, resistant and lysogenic bac-
teria were recovered following treatment with phiCDHM1,
phiCDHM2, or phiCDHM3. Primers specific for individual
phages were used to establish that the recovered bacteria were
genuinely phage resistant or lysogens. The sensitivity of these
strains to each of the individual infecting phages was retested, and
their sensitivities compared to those of untreated bacteria were
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FIG 3 Host range analysis of the seven phages against 80 strains and 21 clinically relevant C. difficile ribotypes found in the United Kingdom, the United States, and
Australia. The host range of the phages was determined using a spot test with 10l of 108 PFU/ml of phage stocks on agar overlays containing cultures of the hosts. (A)
Total number of susceptible ribotypes and strains infected by the phages; (B) percentage of strains per ribotype (RT) susceptible to infection by each of the phages.
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determined. The results showed that the phage-resistant and lyso-
genic isolates were no longer susceptible to the phage against
which they had been tested (except for the lysogenic CD105LC2
strain tested against phiCDHM2). However, they were still sus-
ceptible to at least two of the other phages available in the test pool
(Table 2).
Effects of phage-phage interactions in combinations and
when used in mixed ribotypes in vitro. To determine whether
phages had synergistic or antagonistic effects on each other, a mix-
ture which combined the three most active myoviruses with the
siphovirus phage phiCDHS1 was prepared. Phage phiCDHS1
shows particular specificity for the epidemic 027 ribotype (of
FIG 4 Number of viable C. difficile cells following treatment with phages in vitro. Phage infection was carried out at an MOI of 10. (A, C, and E) CD105HE1
treated with a single phage and two- and three- or four-phage combinations, respectively; (B, D, and F) treatment of CD105LC2 with a single phage and two- and
three- or four-phage combinations, respectively. Viable C. difficile cells in the culture medium were enumerated at the different time points. Error bars represent
the standard errors of the means (SEMs) of three replicates.
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which strain R20291 is frequently used as the exemplar). Infection
with this phage resulted in a 5-log-unit reduction in the viability of
R20291 at 5 h postinfection, with no subsequent change in bacte-
rial counts being observed up to 24 h (see Fig. S2 in the supple-
mental material). Combining this phage (phiCDHS1) with the
other myoviruses had no antagonistic effects on its activity, with
the reduction of R20291 being proportional to the quantity of
phiCDHS1 in the culture.
As infection with multiple ribotypes has been reported (56), we
tested the ability of the phages to target a culture containing two
ribotypes (CD105LC2 ribotype 014/020 and R20291 ribotype
027). The mixed culture was treated with a combination of
phiCDHM1-phiCDHM2-phiCDHM3 (targeting CD105LC2)
and phiCDHS1 (targeting R20291). A 7-log-unit reduction in the
viability of the total C. difficile population was observed at 4 h
posttreatment, although intact bacteria (102 CFU/ml) were iso-
lated by 20 h later (see Fig. S3 in the supplemental material). Using
bacteria recovered from the 24-h culture, 80 colonies were sub-
jected to ribotype analysis, which revealed that only 2 (2.5%) of
the colonies were of the 014/020 ribotype. The relatively low pro-
portion probably reflects the presence of several phages that spe-
cifically target this strain, thus reducing the opportunity for resis-
tance to develop.
Impact of phage combinations on C. difficile in vivo. To es-
tablish the suitability of these phages for therapeutic purposes, we
first determined how effective they were in a hamster model of
CDI. To allow direct comparisons between the in vitro and in vivo
data, we initially determined the virulence of strain CD105HE1 in
the hamster model. Infection with 0.2 ml of 104 CFU/ml
CD105HE1 spores resulted in a typical profile of C. difficile dis-
ease, with all animals displaying classical symptoms of infection (a
wet tail and a drop in the core body temperature to 35°C). All
animals were culled at the established humane endpoint, approx-
imately 55 h postinfection. This time to the endpoint was similar
to that for other C. difficile strains, including CD630	ermB (44 h;
range, 40 to 48 h) and R20291 (47 h; range, 35 to 62 h) (see Table
S4 in the supplemental material). On postmortem examination,
all animals showed high levels of colonization and significant lev-
els of spores and toxin B within the cecum and colon (see Fig. S4A
and B in the supplemental material), where the bacteria are known
to proliferate and tissue damage is most significant.
To determine how effective the phages were at reducing colo-
nization, the animals were treated with 104 CFU/ml spores and 108
PFU/ml individual phages or phage combinations. At every 8 h
postinfection, animals were additionally given 108 PFU/ml indi-
vidual phages or phage combinations, with the animals being
culled at 36 h postinfection (Fig. 1A). This time point was chosen
because in untreated animals, toxin production in the cecum and
colon is limited (with little or no change to Vero cells being ob-
served when they are treated with dilutions of filtered gut sam-
ples), while the recovery of bacteria is consistently high. This al-
lowed us to determine the effects of the phages on colonization in
the absence of toxin-related symptoms. Using the in vitro data and
preliminary experimental data from studies with hamsters in-
fected with individual phages, five different combinations of
phages were chosen and tested in vivo. At 36 h, untreated animals
showed consistently high levels of bacteria and colonization in
the lumen of the cecum and colon (between 106 and 107 CFU/
ml), with 104 to 105 CFU/ml being more intimately associated
with the intestinal epithelial barrier. In animals treated with
phages, the recovered C. difficile CFU counts were significantly
lower in these tissues (Fig. 5A to F). These data show that the most
effective treatment combinations were phiCDHM1-phiCDHM2
and phiCDHM5-phiCDHM6. These treatments reduced the bac-
terial counts from the lumen samples by at least 4 log units and
those from the tissue samples by approximately 2 log units. In
addition, treatment with the four-phage combination (phiCDHM1-
phiCDHM2-phiCDHM5-phiCDHM6) showed levels of reduction
of bacterial counts similar to those achieved with the two-
phage combinations. For at least one animal in each treatment
group, C. difficile was undetectable in various parts of the tissue,
while in others, 104 or 105 CFU/ml per tissue was recovered (Fig.
5A to F).
To determine whether these differences were due to the devel-
opment of phage resistance, 20 individual isolates from the cecum
and colon of treated animals were characterized using multilocus
variable-number tandem-repeat analysis typing (57) (see Fig. S5
in the supplemental material). These molecular profiles con-
firmed that the recovered bacteria were CH105HE1, and in each
case, these bacteria remained sensitive to the phages used in the
treatment. This suggests that the infection outcome may be influ-
enced by the ratio of phage/bacteria during the initial phase of
bacterial outgrowth.
Impact of phage combinationsonC.difficile sporulationand
toxin production in vivo. To determine whether treatment influ-
enced the levels of detectable toxin produced by the bacteria in
vivo, gut filtrates were evaluated for toxin B activity on Vero cells
and toxin A activity on HT-29 cells. As predicted, there was very
little evidence of the presence of active toxin in any of the gut
washes (no cell rounding was observed when filtered gut contents
diluted 1:10 were added) at this time point even in untreated an-
imals. This supports previous observations that toxin is detected
TABLE 2 Susceptibility of phage-resistant bacteria and lysogens to phage infectiona
CD105LC2
strain
Phage titer (PFU/ml)
phiCDHM1 phiCDHM2 phiCDHM3 phiCDHM5 PhiCDHM6
WT 2.0 109 1.5 109 4.0 109 3.0 109 2.0 109
RphiCDHM1 0 4.0 103 1.0 106 2.0 109 2.5 109
LphiCDHM1 3.25 104 0 2.5 108 4.0 109 4.25 109
RphiCDHM2 3.0 103 0 1.5 107 7.25 107 6.5 106
LphiCDHM2 2.5 103 3.0 103 2.5 109 3.5 109 1.5 109
RphiCDHM3 1.5 107 1.0 107 0 0 0
a The susceptibility to phiCDHM1 to phiCDHM3, phiCDHM5, and phiCDHM6 infection was determined using plaque assays on phage-resistant bacteria (RphiCDHM1,
RphiCDHM2, and RphiCDHM3) and lysogens (LphiCDHM1 and LphiCDHM2). The results obtained were compared with those for the wild-type (WT) bacteria.
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only approximately 6 h prior to a drop in body temperature,
which would be significantly later (approximately 49 h) than the
36-h time point used here (58).
The amount of spores recovered from animals treated with
these phage combinations was also significantly lower than the
amount recovered from control animals. In the cecum, these
numbers dropped by approximately 1 log unit in treated ani-
mals compared to the numbers in untreated animals. The drop
in the colon was greater, dropping from 4 log units in untreated
animals to 2 log units in treated animals (P 
 0.011 and P 

FIG 5 Levels of colonization in animals treated with different phage combinations and culled at 36 h postchallenge with CD105HE1. Changes in vegetative cell
populations (A to D) and changes in relative levels of recovered C. difficile spores (E and F) are shown. (A to D) The average total number of LA bacteria recovered
from the cecal contents (A), LA bacteria recovered from the colon (B), TA bacteria recovered from the cecum (C), and bacteria associated with the colon (D) are
presented. (E and F) The number of heat-resistant (spores) LA bacteria from the cecum (E) and the number of spores recovered from the lumen of the colon (F)
are also shown. The median level of colonization is represented, while boxes indicate the upper and lower quartile spread of colonization within the group. The
whisker bars represent the highest and lowest levels of colonization observed from data generated from a minimum number of four animals for each treatment.
WT, wild type.
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0.004 for cecal and colon lumen-associated bacterial spores,
respectively).
Impact of phage combinations on C. difficile in vivo in an
endpointmodel. To further evaluate the efficacy of phage therapy
on disease severity, hamsters were infected as described above and
treated with phage every 8 h until the endpoint of the experiment
(Fig. 1B). The animals were monitored for symptomatic disease
and culled at the humane endpoint described above. Untreated
animals infected with CD105HE1 reached this experimental
endpoint at approximately 55 h postinfection, but infected ani-
mals treated with the four-phage combination (phiCDHM1-
phiCDHM2-phiCDHM5-phiCDHM6) had a clear delay to the ex-
perimental endpoint (87 h 40 min  20 h 28 min) (Fig. 6). This
delay was statistically significant (P
 0.0007) between the treated
and untreated groups, despite the variation in the time to the onset
of symptoms within the treated group.
DISCUSSION
The need for alternative treatments for C. difficile infection has
been widely discussed. In a recent review, Zucca et al. analyzed all
the existing and new developments in this field and highlighted
the key advantages which a bacteriophage-based approach would
offer (12). These include avoidance of microbiome dysbiosis, bac-
terium/host specificity, tolerance by patients, and a lack of inter-
ference with antibiotics (12, 14, 59). Here, we present data on the
characterization of seven phages of C. difficile and describe their
ability to lyse the bacteria and potentially treat CDI in hamsters. In
particular, combinations of phages optimized in vitro were shown
to be effective in the treatment of C. difficile infection in vivo.
While phages with lytic activity against C. difficile have been
described previously (14, 29), their direct therapeutic application
has been limited by the poor availability of multiple phages that
target this pathogen. No strictly virulent C. difficile phages have
been isolated, despite the efforts of several research groups (60–
62). This has hampered their development for therapeutic use, as
temperate phages are considered undesirable due to their capacity
to transduce or lysogenize infected bacteria (30, 31, 34). In reality,
many phage mixtures effective against other target bacteria have
been produced, and in those studies, phages were selected solely
on the basis of their activity in vitro and in vivo (25) and knowledge
of the encoded integrase genes was limited. The phages described
in this study were not strictly virulent, as despite their lytic activity,
their genomes encode integrases. The absence of C. difficile phages
that lack such integrases and the clear lytic properties of the phages
in our collection on a broad range of clinical strains suggest that
the information obtained for these phages provides a strong foun-
dation of knowledge from which further improvements can be
made.
When they were combined, the phages described had lytic ac-
tivity on 86% of the clinically relevant ribotypes (18 of the 21
ribotypes tested). We showed that the phages could lyse 12 of 13 of
the ribotypes that are the most prevalent in the United Kingdom
(63), thus having 92% coverage of such strains, and had 100%
killing efficacy against the emerging ribotypes (ribotypes 002, 005,
014/020, 015, and 078) that are increasingly causing concern in the
United Kingdom and the United States (6, 64, 65). These ribotypes
have also been shown to be associated with increased disease se-
verity and fluoroquinolone resistance (51, 66).
As multiple phages are needed to target the wide range of
strains capable of causing clinical disease, the phages were tested in
combination with each other. Phage cocktails have previously
been shown to be effective in the treatment of Pseudomonas
aeruginosa, Klebsiella pneumoniae, Vibrio cholerae, Clostridium
perfringens, and E. coli in animal models. In all the cases men-
tioned above, phage cocktails have been shown to either reduce
the bacterial load, resulting in full recovery; cause a delay to the
endpoint; or reduce the rate of mortality among the animals (25).
The approach of using phage cocktails is also known to limit the
buildup of resistance and could curtail any problems with phage
lysogeny (25). In order to select these combinations, phages that
had diverse morphologies and infectivity profiles were chosen.
Fundamentally, the efficacy and usefulness of a particular
phage depend upon its host range, with those able to lyse a wide
range of ribotypes being the most suitable for therapeutic pur-
poses. In this study, six of the phages tested individually showed
lytic activity on C. difficile isolates belonging to more than 7 dif-
ferent ribotypes, with phiCDHM3 showing lytic activity on iso-
lates of 12 ribotypes. In contrast, phiCDHM4 lysed isolates from 4
ribotypes but was the only phage that showed any activity against
isolates of ribotype 012. Similarly, inclusion of phiCDHS1 should
be considered in any future combination established for clinical
use, as this was the only phage to infect ribotype 027 and 001
isolates (Fig. 3A and B). These data support the idea that an effec-
tive therapeutic approach will require a combination of phages
and that inclusion of some narrower-host-range phages is neces-
sary to ensure good coverage (41).
In addition to host range, phages need to have robust lytic
properties, and extensive characterization of these activities using
individual phages provided the basis on which the most effective
phage combinations were identified. The capacity of phages to
completely clear cultures of C. difficile was variable, as previously
reported (37, 61, 67), and regrowth of bacteria was observed in all
cases where phages were administered individually. At present, it
is unclear whether this reflects immunity as a consequence of ly-
sogeny to superinfection by the same phage (30, 68) or the devel-
opment of phage resistance (14). However, the fact that recovered
bacteria were still sensitive to other phages in the cocktail supports
the premise that multiple-phage combinations are required for
effective clearance. Regrowth could additionally reflect the chang-
ing physiological conditions of the bacteria within the culture,
which may impact the phage absorption rate, the ability of the
phages to access the bacterial genome, and the burst size (69).
FIG 6 Impact of treatment on survival of animals challenged with
CD105HE1. Untreated animals reached the experimental endpoint earlier
than animals treated with bacteriophage preparation phiCDHM1-
phiCDHM2-phiCDHM5-phiCDHM6. Treated animals received 14 doses of
bacteriophage preparations every 8 h from the point of challenge to the clinical
endpoint. A statistically significant difference in the time to the experimental
endpoint (P
 0.0007) was determined using group sizes of six animals each.
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Interestingly, bacteria recovered in vivo were still sensitive to in-
fection by the phages found in the treatment combinations. This
suggests that the surviving bacteria in vivo had not encountered
the phages either when the phages were present in numbers suffi-
cient to ensure complete lysis or at a time when the bacteria were
physiological insensitive to infection (70, 71).
When the phages were combined, C. difficile clearance was
more effective and the extent of regrowth was either completely
eliminated or significantly reduced. This is consistent with obser-
vations in other bacterial systems (25) and with our data showing
that the phage-resistant bacteria were still susceptible to other
phages tested (Table 2). This observation has been reported for
Lactococcus lactis phage c2, which has been shown to infect lyso-
gens that were created by exposure to a different phage (72).
From these data, it would appear that the effectiveness of
different phage combinations is likely to be influenced by the
sensitivity of the infecting strain. This is illustrated by the fact
that the three-phage combination was more effective at clear-
ing CD105HE1 (ribotype 076), while a four-phage combination
was more efficacious against CD105LC2 (ribotype 014/020). This
suggests that the phage formulation may need to be adjusted to
reflect the targeting of dominant ribotypes (12, 14).
Within the hamster model of infection, we observed that
high titers (107 PFU/ml) of infectious phages could be recov-
ered from the relevant sites of C. difficile colonization, the cecum
and colon. The number of bacteria recovered from animals
treated with combinations of phages was reduced at 36 h (Fig. 5).
Treatment with the three-phage combination phiCDHM2-
phiCDHM5-phiCDHM6 in vivo was less effective than treatment
with any of the two-phage combinations tested. These data sug-
gest that, at least for CD105HE1, the phage phiCDHM1 plays
an important role in clearance, as combinations that included
this phage were the most effective in vivo. Importantly, as the
number of phages in the combination increased, the MOI of the
individual phages in the preparation was reduced. Thus, the three-
phage combination may have been less effective, as addition of a
third poorly effective phage may have reduced the concentration
of the effective phage to a suboptimal concentration within these
experiments. In contrast, inclusion of four phages was highly ef-
fective and probably reflects the lytic activity of phiCDHM1, even
when it was given at a lower dose. Further optimization of the
MOIs of individual phages within this combination should gen-
erate a more effective and optimal treatment. A major highlight of
this work is the correlation between the observations made in vitro
and the corresponding levels of colonization in the animal mod-
els. This gives confidence that the phage combinations tested
against other strains, including CD105LC2 and R20291, will also
be effective in vivo.
In the final animal experiment, using the endpoint regime, we
observed a delay of approximately 33 h between the average time
to the endpoint calculated for the untreated and treated animals.
Although complete protection was not observed, this delay to
symptom onset is consistent with other published data (25).
While single phages have previously been used to treat CDI in
animal models, in both these published studies, vegetative cells
were used to establish infection (29, 30). In those studies, animals
were treated with phage within 1 h of infection with vegetative
cells (29, 30). Using this treatment regimen, it is possible that the
phage could infect and destroy the majority of bacteria during
transit to the cecum and colon. In contrast, animals in this study
were infected with a combination of spores and phages. Evidence
suggests a role for conjugated primary bile acids in C. difficile
germination (73), and therefore, it is unlikely that C. difficile is
sensitive to phage until the spores are exposed to bile in the small
bowel. Using this approach, the interaction between phages and
susceptible germinating vegetative cells is likely to be limited, with
variable numbers of infected and uninfected vegetative cells en-
tering the cecum and colon (25, 71). This could lead to the differ-
ent levels of colonization and disease observed. Interestingly,
lower numbers of spores were recovered from the cecum and colon
of animals receiving the most effective treatments (phiCDHM1-
phiCDHM2, phiCDHM5-phiCDHM6, and phiCDHM1-
phiCDHM2-phiCDHM5-phiCDHM6). As sporulation is gener-
ally a feature of the final stages of infection in animals, these results
suggest that infection had not progressed as rapidly within these
animals. This observation was further supported by the fact that
treated animals showed a significantly longer time to reach the
clinical endpoint.
Further work currently being undertaken will determine
whether phage combinations are effective for the treatment of
low-level colonization. Clearly, it is important to explore how
phages can be modified to improve their activity. This includes the
removal of identified integrases to prevent future integration and
increase burst size. In addition, it will be useful to establish
whether phages can be used as an adjunct to antibiotic therapy,
with their administration alongside or after antibiotic treatment
further reducing the potential of infection relapse. While the in
vivo analysis was performed with only one strain, the correlation
between lysis activities in vitro and in vivo gives confidence that
this approach can be applied more generally. Together these data
provide evidence that phage treatment is a valid approach toward
limiting C. difficile colonization and suggest that this may be a
useful tool in the fight against this infection in the future.
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